MCID: CRV031
MIFTS: 48

Cervical Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 12 58 54 15 17 70
Adenocarcinoma of the Uterine Cervix 12
Adenocarcinoma of the Cervix Uteri 58
Adenocarcinoma Cervix Uteri 12
Adenocarcinoma of Cervix 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3702
NCIt 50 C4029
SNOMED-CT 67 254887002
ICD10 via Orphanet 33 C53.0 C53.1 C53.8
UMLS via Orphanet 71 C0279672
Orphanet 58 ORPHA213772
UMLS 70 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology : 12 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to wolffian duct adenocarcinoma and suppressor of tumorigenicity 3. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Human cytomegalovirus infection and Endometrial cancer. The drugs Epoetin alfa and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, breast and lymph node, and related phenotypes are cellular and digestive/alimentary

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 516)
# Related Disease Score Top Affiliating Genes
1 wolffian duct adenocarcinoma 31.9 KRT7 KRAS ESR1 CALB2
2 suppressor of tumorigenicity 3 31.3 TP53 CDKN2A CDKN1A
3 adenocarcinoma in situ 31.2 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
4 cervical squamous cell carcinoma 31.0 TP53 RASSF1 KRAS EGFR CDKN2A
5 adenocarcinoma 31.0 TP53 KRT7 KRT20 KRAS EGFR CEACAM5
6 squamous cell papilloma 30.9 TP53 CDKN2A
7 clear cell adenocarcinoma 30.9 TP53 KRT7 KRT20
8 ovarian brenner tumor 30.8 KRT7 KRT20 CDKN2A
9 adenosquamous carcinoma 30.8 TP53 KRT7 KRAS EGFR CEACAM7 CEACAM5
10 papillary transitional carcinoma 30.8 TP53 KRT7 KRT20
11 papillary serous adenocarcinoma 30.7 TP53 KRT7 KRT20 KRAS CEACAM5 CALB2
12 serous cystadenocarcinoma 30.7 TP53 KRAS CDKN1A
13 appendix adenocarcinoma 30.7 KRT7 KRT20 KRAS CDX2
14 squamous cell carcinoma 30.7 TP53 KRT7 EGFR CEACAM5 CDKN2A CDKN1A
15 in situ carcinoma 30.7 TP53 ESR1 EGFR CDKN2A
16 breast fibroadenoma 30.6 TP53 RASSF1 ESR1
17 bilateral breast cancer 30.6 TP53 ESR1 CDKN2A
18 mucinous cystadenocarcinoma 30.6 KRT7 KRT20 CEACAM7 CEACAM5
19 cystadenocarcinoma 30.6 TP53 KRT7 CEACAM5 CDKN1A
20 signet ring cell adenocarcinoma 30.5 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
21 endocervical adenocarcinoma 30.5 TP53 KRT7 KRT20 ESR1 CEACAM5 CDX2
22 cervical cancer 30.5 TP53 RASSF1 EBAG9 CDKN2A CDKN1A
23 transitional cell carcinoma 30.4 TP53 KRT7 KRT20 EGFR CDKN2A CDKN1A
24 papilloma 30.4 TP53 RASSF1 KRT7 KRT20 KRAS EGFR
25 chronic cervicitis 30.4 ZNF582 TP53 CDKN2A
26 mammary paget's disease 30.3 KRT7 KRT20 ESR1 EGFR
27 ovarian cystadenocarcinoma 30.2 TP53 KRAS EGFR CEACAM5 CDKN2A CALB2
28 neuroendocrine carcinoma 30.2 KRT7 KRT20 CEACAM5
29 vulval paget's disease 30.1 KRT7 EBAG9 CEACAM5
30 adenoma 30.1 TP53 KRT7 KRT20 KRAS CDX2 CDKN2A
31 uterine carcinosarcoma 30.1 TP53 EGFR CDKN2A
32 small cell carcinoma 30.1 TP53 KRT7 KRT20 KRAS EGFR CDKN2A
33 intestinal obstruction 30.1 KRT7 KRT20 CEACAM5 CDX2
34 ovarian serous carcinoma 30.1 TP53 KRAS CALB2
35 ovary adenocarcinoma 30.1 TP53 KRT7 KRAS ESR1 EGFR CEACAM5
36 endometrial adenocarcinoma 30.0 TP53 KRT7 KRAS ESR1 EGFR CDKN2A
37 endocervical carcinoma 30.0 TP53 KRT7 ESR1 CEACAM5 CDX2 CDKN2A
38 papillary adenocarcinoma 30.0 TP53 KRT7 KRAS CEACAM5
39 endometrial hyperplasia 30.0 TP53 KRAS ESR1
40 papillary carcinoma 30.0 KRT7 KRT20 ESR1 CALB2
41 mucinous adenocarcinoma 30.0 TP53 KRT7 KRT20 KRAS ESR1 EGFR
42 nasopharyngeal carcinoma 29.9 TP53 RASSF1 EGFR CXCL12 CDKN2A
43 myoma 29.8 TP53 KRAS ESR1 EGFR CEACAM5
44 carcinosarcoma 29.8 TP53 KRT7 KRAS EGFR CDKN2A CALB2
45 peritoneum cancer 29.8 TP53 KRT7 EGFR CEACAM5 CDKN2A CALB2
46 renal cell carcinoma, nonpapillary 29.7 TP53 RASSF1 KRT7 KRT20 EGFR CALB2
47 colorectal adenocarcinoma 29.6 TP53 KRT7 KRT20 KRAS EGFR CEACAM5
48 cervix carcinoma 29.6 TP53 MIR362 KRT7 ESR1 EGFR CEACAM5
49 rhabdomyosarcoma 29.5 TP53 KRT7 KRAS ESR1 EGFR CXCL12
50 lynch syndrome 29.4 TP53 KRAS EGFR CDKN2A

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 CDKN1A CDKN2A CDX2 CXCL12 EGFR ESR1
2 digestive/alimentary MP:0005381 10.13 CDKN1A CDKN2A CDX2 EGFR ESR1 KRAS
3 limbs/digits/tail MP:0005371 9.97 CDKN1A CDX2 EGFR ESR1 KRAS LAMC2
4 hearing/vestibular/ear MP:0005377 9.95 CDKN1A EGFR KRAS LAMC2 LRIG1 LRIG3
5 liver/biliary system MP:0005370 9.92 CDKN1A CDKN2A CXCL12 EGFR ESR1 KRAS
6 neoplasm MP:0002006 9.91 CDKN1A CDKN2A CDX2 EGFR ESR1 KRAS
7 no phenotypic analysis MP:0003012 9.81 CDKN1A CDKN2A CXCL12 EGFR ESR1 KRAS
8 normal MP:0002873 9.61 CALB2 CDX2 CXCL12 EGFR ESR1 KRAS
9 skeleton MP:0005390 9.32 CDKN1A CDKN2A CDX2 EGFR ESR1 KRAS

Drugs & Therapeutics for Cervical Adenocarcinoma

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Epoetin alfa Phase 4 113427-24-0
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Vinblastine Approved Phase 3 865-21-4 13342 241903
7
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
8
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
Ifosfamide Approved Phase 3 3778-73-2 3690
11
Gemcitabine Approved Phase 3 95058-81-4 60750
12
Bevacizumab Approved, Investigational Phase 3 216974-75-3
13
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
14
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
15
Tirapazamine Investigational Phase 3 27314-97-2
16 topoisomerase I inhibitors Phase 3
17 Tubulin Modulators Phase 3
18 Antimitotic Agents Phase 3
19 Albumin-Bound Paclitaxel Phase 3
20
Isophosphamide mustard Phase 3 100427
21 Antirheumatic Agents Phase 3
22 Immunosuppressive Agents Phase 3
23 Alkylating Agents Phase 3
24 Antibiotics, Antitubercular Phase 3
25 Mitomycins Phase 3
26 Anti-Bacterial Agents Phase 3
27 Dermatologic Agents Phase 3
28 Immunoglobulins, Intravenous Phase 3
29 Angiogenesis Inhibitors Phase 3
30 Antibodies, Monoclonal Phase 3
31 Immunoglobulin G Phase 3
32 Mitogens Phase 3
33 Endothelial Growth Factors Phase 3
34 Immunologic Factors Phase 3
35 Vaccines Phase 3
36
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
37
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
38
carbamide peroxide Approved Phase 1, Phase 2 124-43-6
39
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
40
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
41
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
44
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
45
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
46
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
47
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
48
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
49
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
50
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
2 Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer Unknown status NCT00039338 Phase 3 cisplatin
3 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
4 A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
5 A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
6 A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes Completed NCT00003078 Phase 3 cisplatin;fluorouracil
7 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
8 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
9 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
10 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
11 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) Recruiting NCT01101451 Phase 3 Cisplatin
12 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Active, not recruiting NCT01672892 Phase 3
13 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
14 An International Multi Center Phase III Study of Chemoradiotherapy Versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
15 Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation Terminated NCT00054067 Phase 3 cisplatin
16 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
17 A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB Unknown status NCT01158248 Phase 2 cisplatin
18 Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
19 Feasibility Study of the Combination of Radiotherapy, Chemotherapy and Hyperthermia for the Treatment of Stage IIB-III-IVA Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
20 Phase I/II Study of Carboplatin in Association With Weekly Oral Topotecan in Patients With Metastatic or Recurrent Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
21 Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
22 CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
23 Phase II Randomized Assessing Pelvic Irradiation Combined With Cisplatin Alone or Cisplatin Plus Cetuximab in Patients With Carcinoma of the Cervix Stage IB2, II and III Completed NCT00957411 Phase 2 cisplatin
24 A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Completed NCT01230996 Phase 1, Phase 2 Cisplatin
25 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
26 A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer Completed NCT00278304 Phase 2
27 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
28 A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
29 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
30 EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA Completed NCT00002562 Phase 2 paclitaxel
31 A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
32 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
33 A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00101192 Phase 2 cisplatin
34 A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
35 Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
36 Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix Completed NCT00003017 Phase 2
37 A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
38 Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
39 A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer Completed NCT00559377 Phase 2
40 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
41 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT01266460 Phase 2
42 A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048) Completed NCT01267253 Phase 2 Brivanib Alaninate
43 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
44 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
45 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
46 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
47 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
48 A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer Completed NCT02880007 Phase 2 Cisplatin
49 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
50 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

40
Cervix, Breast, Lymph Node, Lung, Ovary, Colon, Liver

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 1660)
# Title Authors PMID Year
1
P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. 61 54
20524403 2010
2
Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. 61 54
18202755 2008
3
Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. 54 61
18156982 2008
4
The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. 61 54
17981616 2008
5
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. 54 61
17252195 2007
6
Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. 61 54
17354237 2007
7
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. 61 54
17360030 2007
8
[Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma]. 61 54
17355795 2007
9
Immunohistochemistry as a diagnostic aid in cervical pathology. 61 54
17365826 2007
10
Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. 54 61
16290001 2006
11
Immunohistochemical characterization of endocervical papillary serous carcinoma. 54 61
16515605 2006
12
p16 expression in the female genital tract and its value in diagnosis. 61 54
16462152 2006
13
The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. 54 61
16343183 2005
14
Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. 54 61
15337561 2004
15
The role of the preoperative serum carcinoembryonic antigen level in early-stage adenocarcinoma of the uterine cervix. 54 61
15297173 2004
16
P16 as a molecular biomarker of cervical adenocarcinoma. 54 61
15041997 2004
17
Correlation between MUC5AC expression and the prognosis of patients with adenocarcinoma of the uterine cervix. 61 54
14699032 2004
18
Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using Cdx-2 and a limited immunohistochemical panel. 54 61
14632574 2003
19
CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. 54 61
12877729 2003
20
Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. 61 54
11248419 2001
21
The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. 54 61
11104614 2000
22
Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. 54 61
11006578 2000
23
Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. 61 54
10202666 1999
24
Evaluation of immunostaining for MIB1 and nm23 products in uterine cervical adenocarcinoma. 61 54
9823779 1998
25
Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. 61 54
9635534 1998
26
Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. 61 54
9476065 1998
27
[Relationship between nm23-H1 expression and lymph node metastasis and prognosis in cervical cancer]. 54 61
9772433 1997
28
Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. 61 54
9314589 1997
29
Molecular characterization of adenocarcinoma of the cervix. 61 54
9038270 1997
30
What is a normal CA125 level? 61 54
8175027 1994
31
Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. 61 54
8319181 1993
32
Oestrogen receptor protein and mRNA in adenocarcinoma of the uterine cervix. 61 54
1457356 1992
33
Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. 61 54
2258083 1990
34
Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. 61 54
2317761 1990
35
Mucin leakage into the cervical stroma may increase lymph node metastasis in mucin-producing cervical adenocarcinomas. 61 54
2153042 1990
36
Intensity-modulated radiotherapy combined with intracavitary brachytherapy for locally advanced cervical cancer with uterus didelphys. 61
33718560 2021
37
Prognosis of bulky pTIIB cervical cancer treated by radical hysterectomy comparing adenocarcinoma with squamous cell carcinoma using propensity score matching. 61
33119174 2021
38
Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities. 61
33063290 2021
39
Tumor Necrotic Debris and High Nuclear Grade: Newly Identified High-risk Factors for Early-stage Endocervical Adenocarcinoma. 61
33606367 2021
40
Clinical features and prognostic factors of cervical villoglandular adenocarcinoma. 61
33608452 2021
41
Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma. 61
33009996 2021
42
Adenocarcinoma of the Uterine Cervix: Immunohistochemical Biomarker Expression and Diagnostic Performance. 61
33264105 2021
43
The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists. 61
33570867 2021
44
Influence of core extension and side chain nature in targeting G-quadruplex structures with perylene monoimide derivatives. 61
33550073 2021
45
Crucial cytotoxic and antimicrobial activity changes driven by amount of doped silver in biocompatible carbon nitride nanosheets. 61
33714189 2021
46
Characteristics of human papillomavirus infection among women with cervical cytological abnormalities in the Zhoupu District, Shanghai City, China, 2014-2019. 61
33685499 2021
47
Rapid identification of cervical adenocarcinoma and cervical squamous cell carcinoma tissue based on Raman spectroscopy combined with multiple machine learning algorithms. 61
33212265 2021
48
Novel silver glycinate conjugate with 3D polymeric intermolecular self-assembly architecture; an antiproliferative agent which induces apoptosis on human breast cancer cells. 61
33461021 2021
49
Chemical composition, biological properties and bioinformatics analysis of two Caesalpina species: A new light in the road from nature to pharmacy shelf. 61
33730614 2021
50
Options for triage and implications for colposcopists within European HPV-based cervical screening programmes. 61
33524777 2021

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 TP53 KRAS EGFR CXCL12 CDKN2A CDKN1A
2
Show member pathways
12.71 TP53 KRAS EGFR CDKN2A CDKN1A
3
Show member pathways
12.58 TP53 KRAS ESR1 EGFR CDX2 CDKN2A
4 12.45 TP53 RASSF1 KRAS EGFR CDKN2A CDKN1A
5 12.33 TP53 RASSF1 LAMC2 KRAS ESR1 EGFR
6
Show member pathways
12.3 TP53 RASSF1 KRAS ESR1 EGFR CDKN2A
7 12.24 TP53 KRAS CDKN2A CDKN1A
8 12.2 TP53 KRAS ESR1 EGFR CDKN1A
9 12.19 TP53 KRAS CDKN2A CDKN1A
10 12.09 TP53 KRAS EGFR CDKN1A
11 12.06 TP53 KRAS CDKN2A CDKN1A
12 12.04 TP53 KRAS ESR1 EGFR
13 11.97 KRT20 KRAS ESR1 EGFR EBAG9
14 11.9 TP53 KRAS CDKN2A CDKN1A
15 11.76 TP53 KRAS EGFR CDKN2A CDKN1A
16
Show member pathways
11.69 LRIG1 KRAS ESR1 EGFR CXCL12
17 11.65 TP53 CDKN2A CDKN1A
18 11.63 TP53 KRAS EGFR
19 11.47 TP53 EGFR CDKN2A CDKN1A
20 11.39 KRAS ESR1 EGFR CDKN1A
21 11.13 RASSF1 KRAS EGFR
22
Show member pathways
11.03 TP53 CDKN2A CDKN1A
23 10.96 TP53 RASSF1 KRAS EGFR CDKN2A CDKN1A
24 10.7 TP53 CDKN1A
25
Show member pathways
10.49 TP53 CDKN1A

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.1 TP53 ESR1 EGFR CDX2 CDKN2A CDKN1A

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein stabilization GO:0050821 9.67 TP53 RASSF1 CDKN2A CDKN1A
2 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.58 MIR362 CDKN2A CDKN1A
3 cell cycle arrest GO:0007050 9.56 TP53 RASSF1 CDKN2A CDKN1A
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 TP53 EGFR
5 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.46 TP53 ESR1
6 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.43 TP53 ESR1
7 signal transduction by p53 class mediator GO:0072331 9.32 TP53 CDKN1A
8 otolith morphogenesis GO:0032474 9.16 LRIG3 LRIG1
9 replicative senescence GO:0090399 9.13 TP53 CDKN2A CDKN1A
10 Ras protein signal transduction GO:0007265 9.02 TP53 RASSF1 KRAS CDKN2A CDKN1A

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 TP53 ESR1 EGFR CDKN2A CDKN1A
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN1A
3 MDM2/MDM4 family protein binding GO:0097371 8.96 TP53 CDKN2A
4 nitric-oxide synthase regulator activity GO:0030235 8.62 ESR1 EGFR

Sources for Cervical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....